By: Ronald de Wit; MD , PhD
The positive outcome of several randomized clinical trials evaluating immune checkpoint inhibitors in patients with metastatic bladder cancer dramatically changed the treatment paradigm in this setting. In his presentation, Prof. de Wit summarized the clinical data generated with PD-1/PD-L1 inhibitors in this setting, but he kicked off by summarizing the historical results obtained with chemotherapy in patients with metastatic urothelial cancer.
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
